There's a growing recognition that the molecular profile of a primary tumor can differ significantly from its metastases. To guide treatment more accurately, the preferred practice is to biopsy an accessible metastatic lesion when possible, as this better reflects the biology of the active disease being treated.

Emerging data indicates that Tarlatamab, a DLL3-targeted therapy, has inferior performance in small cell lung cancer (SCLC) that transformed from EGFR-mutant NSCLC compared to its efficacy in de novo SCLC. This suggests the biological context of transformation impacts treatment response, a critical nuance for this new therapy.

When a liquid biopsy fails to detect the original EGFR driver mutation in a patient progressing on therapy, it should not be interpreted as the cancer losing its dependency. This result more likely indicates insufficient tumor DNA shedding, signaling that the test is uninformative and a tissue biopsy is needed.

Dr. Suresh Ramalingam simplifies the concept of different EGFR exon mutations by comparing them to specific accident locations on a long street. This highlights the need for precise genomic information to choose the right treatment "detour," making a complex topic accessible to trainees and patients.

When patients with EGFR-mutated lung cancer progress on osimertinib, a re-biopsy is essential not just for new genomic markers. It's critical for identifying histologic transformation to small cell or squamous cell cancer, which mandates a complete switch to chemotherapy-based regimens.

Patients with EGFR-mutant NSCLC that transforms into small cell lung cancer show poor responses to new therapies like tarlatamab, which are highly effective in de novo small cell cancer. This highlights a distinct biology that requires different therapeutic strategies and dedicated clinical trials.

When EGFR+ NSCLC transforms to small cell, clinicians often continue the TKI osimertinib alongside chemotherapy. This practice is largely based on expert consensus and the rationale of suppressing any remaining EGFR-driven clones, rather than on definitive clinical trial data showing a clear benefit.

The ongoing SWOG PRISM study represents a paradigm shift for small cell lung cancer (SCLC). By analyzing gene expression profiles to identify molecular subtypes during initial therapy, the trial aims to assign patients to different targeted agents. This moves away from the current one-size-fits-all strategy towards a personalized approach based on underlying tumor biology.

The ADAURA trial's MRD analysis reveals that a negative ctDNA test after surgery is not a reliable indicator of being cured. Patients still require adjuvant therapy, as recurrence remains a significant risk, especially within 12 months after stopping treatment.